-
Octapharma USA reintroduces Octagam 5%
HOBOKEN, N.J. — A drug for treating immune system disorders is available again following a voluntary market withdrawal last summer.
Octapharma USA said Wednesday that Octagam (immune globulin intravenous [human] 5% liquid preparation) again was available for purchase. The Food and Drug Administration approved its reintroduction on Nov. 3.
-
Pfizer completes Excaliard acquisition
NEW YORK — Pfizer completed its acquisition of a drug maker that focuses on the development of skin scarring treatments.
Pfizer said its acquisition of Excaliard Pharmaceuticals will allow the company to develop "new and innovative treatments to address unmet medical needs," noting that there currently is no excessive skin scarring treatment approved by the Food and Drug Administration.